Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – HC Wainwright reduced their Q1 2026 earnings per share (EPS) estimates for shares of Bradmer Pharmaceuticals in a research note issued on Wednesday, February 4th. HC Wainwright analyst M. Colonnese now anticipates that the company will post earnings of ($0.68) per share for the quarter, down from their previous estimate of ($0.11). HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2026 earnings at ($0.04) EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.16 EPS and FY2026 earnings at ($0.44) EPS.
Separately, Citizens Jmp upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, December 9th. Six equities research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Strong Buy”.
Bradmer Pharmaceuticals Stock Performance
Further Reading
- Five stocks we like better than Bradmer Pharmaceuticals
- NEW LAW: Congress Approves Setup For Digital Dollar?
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- What a Former CIA Agent Knows About the Coming Collapse
- Trade this between 9:30 and 10:45 am EST
- When to buy gold (mathematically)
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
